| Name | Title | Contact Details |
|---|
ProNAi Therapeutics is a clinical-stage oncology company pioneering a novel class of therapeutics based on its proprietary DNAi technology platform for patients with cancer and hematological diseases. ProNAi`s lead DNAi product candidate, PNT2258, is designed to treat cancers that overexpress BCL2, an important and validated oncogene known to be dysregulated in many types of cancer. ProNAi is pursuing a multi-faceted clinical development strategy designed to efficiently achieve regulatory approval and maximize the commercial opportunity of PNT2258. ProNAi recently initiated "Wolverine", a Phase 2 trial evaluating PNT2258 for the treatment of relapsed or refractory diffuse large B-cell lymphoma.
Psych Hub is the worlds largest online platform for mental health education. We train mental health providers, employers, organizations, and individuals on mental health.
PharmaPix is a Naperville, IL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Sumitomo Pharma is a pharmaceutical company that develops innovative pharmaceuticals and healthcare solutions for the betterment of healthcare and fuller lives of people worldwide.
Peer Direct is a New York, NY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.